about
Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activityCharacterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic painThe regulation of liver cytochrome p450 by the brain dopaminergic system.Regulation of liver cytochrome P450 by activation of brain dopaminergic system: physiological and pharmacological implications.Effects of low doses of intracerebroventricular 6-OHDA on the levels of monoaminergic neurotransmitters in rat brain structures.Cytochrome P450 mediates dopamine formation in the brain in vivo.Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder.Striatal adenosine A(2A) receptor blockade increases extracellular dopamine release following l-DOPA administration in intact and dopamine-denervated rats.Chronic treatment with zinc and antidepressants induces enhancement of presynaptic/extracellular zinc concentration in the rat prefrontal cortexThe mechanism of 1,2,3,4-tetrahydroisoquinolines neuroprotection: the importance of free radicals scavenging properties and inhibition of glutamate-induced excitotoxicity.Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102,677.The antipsychotic-like effects in rodents of the positive allosteric modulator Lu AF21934 involve 5-HT1A receptor signaling: mechanistic studies.The role of brain noradrenergic system in the regulation of liver cytochrome P450 expression.Preclinical evaluation of the abuse potential of the analgesic bicifadine.The cytochrome P450 2D-mediated formation of serotonin from 5-methoxytryptamine in the brain in vivo: a microdialysis study.The role of the dorsal noradrenergic pathway of the brain (locus coeruleus) in the regulation of liver cytochrome P450 activity.Effect of adenosine A(2A) receptor antagonists and L-DOPA on hydroxyl radical, glutamate and dopamine in the striatum of 6-OHDA-treated ratsMelatonin Supports CYP2D-Mediated Serotonin Synthesis in the Brain.5-HT7 receptor modulates GABAergic transmission in the rat dorsal raphe nucleus and controls cortical release of serotoninThe effect of adenosine A(2A) receptor antagonists on hydroxyl radical, dopamine, and glutamate in the striatum of rats with altered function of VMAT2Effect of Some Psychoactive Drugs Used as 'Legal Highs' on Brain NeurotransmittersEffects of adenosine receptor antagonists on the in vivo LPS-induced inflammation model of Parkinson's disease.Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats.Group III mGlu receptor agonist, ACPT-I, exerts potential neuroprotective effects in vitro and in vivoSelective mGluR1 antagonist EMQMCM inhibits the kainate-induced excitotoxicity in primary neuronal cultures and in the rat hippocampus.Partial lesion of the dopaminergic innervation of the ventral striatum induces "depressive-like" behavior of rats.Accumbal and pallidal dopamine, glutamate and GABA overflow during cocaine self-administration and its extinction in rats.Pharmacological characterization of MP349, a novel 5-HT1A-receptor antagonist with anxiolytic-like activity, in mice and rats.Distinct retinoic acid receptor (RAR) isotypes control differentiation of embryonal carcinoma cells to dopaminergic or striatopallidal medium spiny neurons.Neuroprotective potential of mGluR5 antagonist MTEP: effects on kainate-induced excitotoxicity in the rat hippocampus.Effect of metyrapone on the fluoxetine-induced change in extracellular dopamine, serotonin and their metabolites in the rat frontal cortex.Treatment with 1,2,3,4,-tetrahydroisoquinoline affects glutamate release in the striatum but not the binding of [3H]MK-801 to NMDA receptors in the dopaminergic structures of the rat brain.Mazindol attenuates ketamine-induced cognitive deficit in the attentional set shifting task in rats.1-Methyl-1,2,3,4-tetrahydroisoquinoline antagonizes a rise in brain dopamine metabolism, glutamate release in frontal cortex and locomotor hyperactivity produced by MK-801 but not the disruptions of prepulse inhibition, and impairment of working memThe effect of caffeine on MDMA-induced hydroxyl radical production in the mouse striatum.Differential effects of chronic haloperidol and clozapine administration on glutamatergic transmission in the fronto-parietal cortex in rats: microdialysis and electrophysiological studies.Glutamate input to noradrenergic neurons plays an essential role in the development of morphine dependence and psychomotor sensitization.Inhibition of amino acid release by 5-HT1B receptor agonist in the rat prefrontal cortex.The effect of risperidone on the mirtazapine-induced changes in extracellular monoamines in the rat frontal cortex.Effect of the adenosine A2A receptor antagonist 8-(3-chlorostyryl)caffeine on L-DOPA biotransformation in rat striatum.
P50
Q28256557-2F3C01F4-6419-4A01-914E-6933B8CF608DQ28290309-B8C961F2-7E01-4E46-8D59-F47F14093DDDQ33293850-7A97F2C2-9ED9-42D0-A4DA-C3D20A748E49Q33341290-9AD3AB8B-C545-4867-AEBA-E11694B6BC26Q33805837-B1DBBD69-9B8A-456F-9811-0A2701B58B05Q33925984-B3449AC7-89E2-44DF-BE8C-575F99856C64Q34251275-47C01B21-63B2-4B90-8D7A-C7CB8B1A3AAEQ34336032-D5E3C760-0696-4F08-87D3-579B591A2364Q34466775-A17B7DC1-D1F8-4CE9-BC81-2BC4204698A2Q34499446-8F62DEB5-0A9D-40BD-AEAD-92A46A4A5970Q34517414-9BEBE6EA-3AAB-472A-872F-1DEF48776B64Q34798345-630102A3-188D-4CE4-A4B6-3F87D06F093CQ34909179-3719B794-D115-41C3-9F69-B97EFFD20D9EQ35453895-2BD7C8D2-2896-4868-9D57-9D024D3C4242Q35541620-8C55FEB3-4BF1-4411-BB52-DC9EF785A873Q35552388-DD7E6679-B6F4-4F23-9DA2-019F04F87BB6Q35635814-A951B7DB-6595-4C2C-AEAA-C77CFF321E16Q35925626-3B597880-05E9-4273-8E8F-679F2953BAA9Q35964136-75ABC17F-1B2F-4F76-A4B6-B59EF2B7C039Q36010835-BCC1FF57-0073-48F8-9BA9-ED62B8DA0FFDQ36674322-88FCBBF9-FBBC-4E95-929B-833D0C751A2CQ36882447-F5A23C61-8F99-44BF-891E-E1C8687FD8FAQ37306537-0F0176D0-B61B-4FC3-9062-017A982740ECQ39982710-43548A4E-64F4-440F-882C-B2EEE5D85D37Q41811282-54A8AC86-A1BD-4DC7-84AB-DBE5A3EF1311Q42502496-6468CD73-1F9E-496A-A337-9F435DC23763Q42519150-00EB7CA1-25B2-4839-8AA3-482DFCCA1F90Q42601434-C52A60BD-42AF-448F-9C88-8CE7B5E612AFQ42652784-DB456025-A5DF-4B4D-BA9E-0984BFA970A2Q42754399-CC5BD137-5EA2-4CA4-A2AC-9219C4D02291Q42754409-517800BE-C35A-47FF-B2BC-1AAE4ABB2795Q43244749-B4925C58-F1F2-4781-AB9B-1A498190B110Q43281231-CE313EB2-454C-4DFC-AFDC-79EFF02A5E74Q43299739-6CDF46DE-339E-4AF9-A1A6-A87A36B68316Q43837500-882D9EF9-432F-4E0C-A910-BBB8E454A5FEQ44181358-C014AB97-E027-45E7-AA75-7B2701E3EB77Q44394260-C7B52996-EE03-4095-8D13-A863244F75D8Q44515597-A8AE3663-2043-4F0B-8A7B-C7C35442268AQ44596283-408F948E-CE53-44AC-8EEF-2BCCF7BB78A2Q44748458-02737E08-4283-42C3-B509-B84F9BBBC704
P50
description
Forscher
@de
Polish pharmacologist
@en
Pools farmacologe
@nl
chercheur
@fr
hulumtuese
@sq
investigador
@es
polska farmakolog
@pl
ricercatore
@it
研究者
@zh
name
Krystyna Gołembiowska
@ast
Krystyna Gołembiowska
@ca
Krystyna Gołembiowska
@cs
Krystyna Gołembiowska
@en
Krystyna Gołembiowska
@es
Krystyna Gołembiowska
@gl
Krystyna Gołembiowska
@hr
Krystyna Gołembiowska
@hsb
Krystyna Gołembiowska
@it
Krystyna Gołembiowska
@nl
type
label
Krystyna Gołembiowska
@ast
Krystyna Gołembiowska
@ca
Krystyna Gołembiowska
@cs
Krystyna Gołembiowska
@en
Krystyna Gołembiowska
@es
Krystyna Gołembiowska
@gl
Krystyna Gołembiowska
@hr
Krystyna Gołembiowska
@hsb
Krystyna Gołembiowska
@it
Krystyna Gołembiowska
@nl
altLabel
Krystyna Czesława Gołembiowska
@pl
prefLabel
Krystyna Gołembiowska
@ast
Krystyna Gołembiowska
@ca
Krystyna Gołembiowska
@cs
Krystyna Gołembiowska
@en
Krystyna Gołembiowska
@es
Krystyna Gołembiowska
@gl
Krystyna Gołembiowska
@hr
Krystyna Gołembiowska
@hsb
Krystyna Gołembiowska
@it
Krystyna Gołembiowska
@nl
P214
P106
P1412
P1559
Krystyna Gołembiowska
@pl
P21
P214
P27
P31
P3124
P496
0000-0002-5018-1394
P7859
viaf-311123844